PDS Biotechnology Corporation
PDSB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | 0.00 | 0.31 | 0.08 |
| FCF Yield | -50,765.09% | -14.91% | -18.73% | -13.86% |
| EV / EBITDA | 3,317.67 | -6.55 | -3.12 | -5.78 |
| Quality | ||||
| ROIC | -38.00% | -22.10% | -19.37% | -18.03% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.66 | 0.96 | 1.06 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -263,947.65% | -0.76% | -9.69% | -2.93% |
| Safety | ||||
| Net Debt / EBITDA | 3,323.69 | 1.83 | 2.41 | 2.90 |
| Interest Coverage | -7,076.06 | -3.55 | -9.78 | -6.72 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -5,134.53 |